News - Pharmaceuticals
Endocrinologists welcome PBS listing of first thyroid HRT not requiring refrigeration

Pharma News: Australia’s first reimbursed thyroid hormone replacement therapy not requiring refrigeration is now listed on the Pharmaceutical Benefits Scheme (PBS).
Sun Pharma’s Levoxine (levothyroxine sodium), bioequivalent to Aspen’s Oroxine and Eutroxsig, is a thyroid hormone replacement therapy (HRT) listed for the management of hypothyroidism, and for thyroid tumours which are responsive to thyroid-stimulating hormone (TSH).
According to Senior Endocrinologist in the Department of Endocrinology and Diabetes, Alfred Hospital, Professor Duncan Topliss, Melbourne, finding the right treatment option for the one in 33 Australians living with our nation’s most common thyroid disorder is critical to improving patient outcomes.
“Although there is currently no cure for hypothyroidism, the disorder can be effectively managed with thyroid HRT. However, given patients with hypothyroidism require life-long, daily medication, there remain challenges with treatment adherence, with up to one in three patients reporting some level of non-compliance,” said Prof Topliss.
“If left uncontrolled, or ineffectively managed, hypothyroidism can cause serious health issues, including cardiovascular disease, infertility, neurological and gastrointestinal symptoms, and in severe cases, can rarely even prove fatal.
“Therefore, having a subsidised treatment option not requiring refrigeration, and with distinguishable tablet strengths, offers healthcare professionals additional treatment options that may better suit some patients’ needs,” Prof Topliss said.
Consultant Endocrinologist at St Vincent’s Hospital and Northern Endocrine, Dr Kiernan Hughes, Sydney, said early diagnosis and effective management of hypothyroidism is critical to improving patient quality of life.
“Almost 780,000 Australians are living with hypothyroidism. Those affected often experience extreme exhaustion and other debilitating symptoms that significantly interfere with daily life. Concerningly, people living with hypothyroidism may experience significant psychological symptoms, including emotional instability, forgetfulness, and mental slowness.
“Furthermore, up to 60% of those affected report some level of depression,” said Dr Hughes.
Given the management of hypothyroidism is not a ‘one size fits all’ approach, there is a crucial need for individualised treatments for hypothyroidism, explained Dr Hughes.
“In most cases, people diagnosed with hypothyroidism require daily treatment with HRT for the rest of their lives. The dose should be individualised on the basis of clinical response and biochemical tests, to ensure the concentration of thyroxine and TSH remains within the normal range.
“The availability of another thyroid HRT on the PBS provides another treatment option for Australians living with hypothyroidism, and may help minimise the disorder’s impact on the daily lives of those affected,” Dr Hughes said.
Levoxine is now available in pharmacies and is ‘a’-flagged with the reference ‘levothyroxine’, meaning substitution can occur at any stage of dispensing.
Levoxine is not bioequivalent on a same-dose basis with Eltroxin. If a decision is made to switch a patient from Eltroxin to Levoxine, prescribers should have a plan for monitoring (TSH), and be aware that dose adjustment may be required
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More